Fulipiftide clinical trials
Also written BRM421.
How each study uses fulipiftide is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the fulipiftide studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your alerts, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your alerts. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Development codes
- BRM421
- 2
Studies by the year they started
5 studies that test it; most in 2017 (1)
| Year | Studies |
|---|---|
| 2017 | 1 |
| 2020 | 1 |
| 2023 | 1 |
| 2024 | 1 |
| 2025 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 5 · Other 0
BRIM Biotechnology Inc. (5)
Often tested with
Tested in the same studies.
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Reaching primary completion within a year · 1
Studies that test fulipiftide.
- Nov 2026A Dose Regimen Study of BRM421 Ophthalmic Solution in Patients With Dry Eye DiseasePhase 2 · BRIM Biotechnology Inc.
Studies
Open first, then newest update. How each study uses fulipiftide is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 5
- A Dose Regimen Study of BRM421 Ophthalmic Solution in Patients With Dry Eye DiseaseNot yet recruitingPhase 2BRIM Biotechnology Inc.NCT07078955Written as BRM421 Ophthalmic Solution, 0.03%
- Assessment of the Initial Efficacy and Safety of BRM424 Ophthalmic Solutions in Patients With Neurotrophic KeratitisRecruitingPhase 2BRIM Biotechnology Inc.NCT05927428Written as BRM424 Ophthalmic Solution - Dose1
- Safety and Efficacy of BRM421 for Dry Eye SyndromeCompletedPhase 2BRIM Biotechnology Inc.NCT03066219Written as BRM421
- Safety and Efficacy of BRM421 for Dry Eye Syndrome TreatmentCompletedPhase 2/3BRIM Biotechnology Inc.NCT04343287Written as BRM421
- Assessment of the Safety and Efficacy of BRM421 Ophthalmic Solutions in Dry Eye Subjects.CompletedPhase 3BRIM Biotechnology Inc.NCT05695781Written as BRM421 Ophthalmic Solution
Codes
What other systems call fulipiftide · ClinicalTrials.gg INT017370
- UNII (FDA) N9MH3WI51MFULIPIFTIDEOne source FDA
- NCI Thesaurus C213409FulipiftideOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | N9MH3WI51M | FULIPIFTIDE | One source FDA |
| NCI Thesaurus | C213409 | Fulipiftide | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.